{"id":"nu100","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Headache"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"NU100 works by selectively modulating the sphingosine-1-phosphate 1 (S1P1) receptor, which plays a key role in the regulation of lymphocyte trafficking and immune responses.","oneSentence":"NU100 is a small molecule that targets the S1P1 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:23:38.163Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsing forms of multiple sclerosis"}]},"trialDetails":[{"nctId":"NCT01464905","phase":"PHASE3","title":"Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)","status":"UNKNOWN","sponsor":"Nuron Biotech Inc.","startDate":"2011-10","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":500}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"NU100","genericName":"NU100","companyName":"Nuron Biotech Inc.","companyId":"nuron-biotech-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"NU100 is a small molecule that targets the S1P1 receptor. Used for Relapsing forms of multiple sclerosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}